|
Sunday, 08/01/2010
|
Novel Phase I Design for Oncology Research
Linda Sun, Merck & Co., Inc.; Keaven M. Anderson, Merck Research Laboratories; Lisa Lupinacci, Merck & Co., Inc.; Yevgen Tymofyeyev, Merck & Co., Inc.
2:05 PM
|
Slice Sampling with Adaptive Multivariate Steps: The Shrinking-Rank Method
Madeleine Thompson, University of Toronto; Radford Neal, University of Toronto
2:05 PM
|
Partnership in New Drug Developments
Ji Zhang, Sanofi-Aventis; Hui Quan, sanofi-aventis; Alex Boddy, sanofi-aventis; Peng-Liang Zhao, sanofi-aventis; Stan Young, National Institute for Statistical Science
2:25 PM
|
Adaptive Confidence Intervals for Regression Coefficients in Q-Learning
Eric B. Laber, University of Michigan; Min Qian, University of Michigan; Susan Murphy, University of Michigan
2:35 PM
|
A Perturbation Method for Inference on Adaptive LASSO Regression Estimates
Jessica Minnier, Harvard University; Tianxi Cai, Harvard School of Public Health
2:35 PM
|
Adaptive Designs in Dose-Finding Oncology Drug Combination Trials
Yuehui Wu, GlaxoSmithKline; Bingming Yi, GlaxoSmithKline; Yanmei Xu, GlaxoSmithKline
2:45 PM
|
Identifying QTLs in Plant Breeding Populations with Adaptive Mixed LASSO
Dong Wang, University of Nebraska-Lincoln; Kent M. Eskridge, University of Nebraska-Lincoln; Jose Crossa, International Maize and Wheat Improvement Center
2:50 PM
|
Expect the Unexpected: Bayesian Adaptive Dose-Finding Design in Proof-of-Concept Study
Feng Liu, GlaxoSmithKline
3:25 PM
|
Bayesian Adaptive Designs for Dose Escalation Studies
Anna Elizabeth McGlothlin, Eli Lilly and Company
4:05 PM
|
Two-Stage Adaptive Design for Bioequivalence: Methods and Application
Yi-Lin Chiu, Abbott Global Pharmaceuticals Research and Development; Yannis Jemiai, Cytel Inc.; Charles Locke, Abbott Laboratories; Pralay Senchaudhuri, Cytel Inc.
4:25 PM
|
Using Bayesian Adaptive Designs for FDA Event Safety Studies
Jason Connor, Berry Consultants, LLC; Scott Berry, Berry Consultants, LLC; Donald Arthur Berry, MD Anderson Cancer Center
4:45 PM
|
A Bayesian Dose-Finding Design Adapting to Efficacy and Tolerability Response
S. Krishna Padmanabhan, Pfizer Inc.; Scott Berry, Berry Consultants, LLC; Vladimir Dragalin, Pfizer Inc.; Michael Krams, Pfizer Inc.
5:05 PM
|
Adaptive Estimation in High-Dimensional Response Surface Models via Iterative Thresholding Regularization
Samir Touzani, French Institut of Petroleum; Anestis Antoniadis, University Joseph Fourier; Daniel Busby, French Institut of Petroleum
5:20 PM
|
|
Monday, 08/02/2010
|
Erosion Prediction with USLE and RUSLE2
Yang Li, Iowa State University
|
Adaptive Confidence Intervals for the Test Error in Classification
Eric B. Laber, University of Michigan
|
To Adjust or Not to Adjust?: Simple vs. Adaptive/Forced Randomization
Yuko Y. Palesch, Medical University of South Carolina
|
Implementation of EWOC (Escalation With Overdose Controls) Adaptive Dose-Finding Design in a Phase IIA Clinical Trial
Catherine Bresee, Oschin Comprehensive Cancer Institute; Amir Steinberg, Oschin Comprehensive Cancer Institute; Jeremy Rudnick, Oschin Comprehensive Cancer Institute; Andre Rogatko, Oschin Comprehensive Cancer Institute
|
A General Framework of Adaptive Designs for Early-Phase Oncology Clinical Trials
Lixin Lang, Bristol-Myers Squibb; Ralph Raymond, Bristol-Myers Squibb
|
Two-Stage Adaptive Design for Case-Control Genetic Association Studies
Lihan Yan, FDA
9:15 AM
|
Adaptive Factorial Designs for Combination Therapy in Oncology
Donald Arthur Berry, MD Anderson Cancer Center
9:15 AM
|
Asymptotic Behavior of Weights in the Adaptive Regression by Mixing
Chihche Lin, Astellas Pharma Global Development, Inc.; Yuhong Yang, University of Minnesota
9:20 AM
|
A Multivariate Penalized Regression Method for eQTL Mapping
Ting-Huei Chen, The University of North Carolina at Chapel Hill; Wei Sun, The University of North Carolina at Chapel Hill; Fred Wright, The University of North Carolina at Chapel Hill
9:20 AM
|
Optimal Two-Stage Phase II Design Utilizing Partial Information for Long-Term Endpoints
Bo Huang, Pfizer Inc.; Enayet Talukder, Pfizer Inc.; Neal Thomas, Pfizer Inc.
9:35 AM
|
Achieving the Benefits of Both an Internal Pilot and Interim Analysis in Small Samples
John A. Kairalla, University of Florida; Keith E. Muller, University of Florida; Christopher S. Coffey, The University of Iowa
10:35 AM
|
Adaptive Bayesian Calibration of Computer Models Using Sequential Monte Carlo
Gardar Johannesson, Lawrence Livermore National Laboratory
10:35 AM
|
Adaptive Gaussian Predictive Process Model for Large Spatial Data Sets
Rajarshi Guhaniyogi, University of Minnesota; Andrew Finley, Michigan State University; Sudipto Banerjee, University of Minnesota; Alan E. Gelfand, Duke University
11:05 AM
|
Applications of 'Learn' Phase Adaptive Designs
Jose Carlos Pinheiro, Johnson & Johnson; Chyi-Hung Hsu, Novartis Pharmaceuticals Corporation
2:05 PM
|
Adaptive Design for Sample Size Re-estimation in a Medical Device Trial of Spinal Cord Stimulation
Nitzan Mekel-Bobrov, Boston Scientific Corporation
2:05 PM
|
High-Dimensional Adaptive Basis Density Estimation
Susan Buchman, Carnegie Mellon University; Ann Lee, Carnegie Mellon University; Chad Schafer, Carnegie Mellon University
2:05 PM
|
Adaptive Sample Size Re-estimation When Interim Results Are Promising
Cyrus R. Mehta, Cytel Inc.
2:25 PM
|
Guiding Clinicans Through the EffTox Model
Meagan E. Spychala, Rho, Inc.
2:35 PM
|
An Adaptive Noninferiority Study
Pilar Lim, Johnson & Johnson; Qing Liu, Johnson & Johnson; Rosanne Lane, Johnson & Johnson; Barry Schwab, Johnson & Johnson; Allan Sampson, University of Pittsburgh
2:45 PM
|
Iteratively Reweighted Smoothing Splines
Heeyoung Kim, Georgia Institute of Technology; Xiaoming Huo, Georgia Institute of Technology
2:50 PM
|
Evaluation of Design Parameters for an Adaptive Seamless Phase 2b/3 Trial
Susan Y. Zhou, CDER/FDA; Greg Soon, CDER/FDA; Xiao Ding, CDER/FDA; JungYeon Park, CDER/FDA; EunYoung Kim, CDER/FDA; Sue-Jane Wang, FDA
3:05 PM
|
Adaptations That Should Not Raise Objections, but Probably Will
Michael Proschan, National Institute of Allergy and Infectious Diseases
3:25 PM
|
|
Tuesday, 08/03/2010
|
Design, Implementation, and Results for a Bayesian Adaptive Randomization Trial for Targeted Therapy in Lung Cancer
Suyu Liu, MD Anderson Cancer Center; J. Jack Lee, MD Anderson Cancer Center
|
Disparity-Aided Robust and Efficient Inference for Adaptive Designs with Covariates
Anand Vidyashankar, George Mason University
8:35 AM
|
The Polya Tree Sampler: Towards Efficient and Automatic Independent Metropolis Proposals
Alejandro Jara, Pontificia Universidad Católica de Chile; Timothy Edward Hanson, University of Minnesota; Joao Monteiro, University of Minnesota
8:35 AM
|
Bayesian Nonparametric Intensity Estimation for Inhomogeneous Spatial Point Processes
Yu Ryan Yue, Baruch College, CUNY; Ji Meng Loh, AT&T Labs - Research
9:15 AM
|
Estimation of Treatment Effect Following a Clinical Trial with Adaptive Design
Xiaolong Luo, Celgene Corporation; Peter Ouyang, Celgene Corporation
9:20 AM
|
A Graphical Approach to Multiple Test Procedures for Adaptive Phase II/III Clinical Trials
Martin Posch, Medical University of Vienna
9:25 AM
|
Regularized Gaussian Mixture Modeling with Adaptive Covariance Shrinkage
Hyang Min Lee, Penn State; Jia Li, Penn State
9:55 AM
|
A Bayesian Adaptive Design with Biomarkers for Targeted Therapies
Jens C. Eickhoff, Colorado State University; KyungMann Kim, University of Wisconsin-Madison; Jill M. Kolesar, University of Wisconsin-Madison; Jason R. Gee, Lahey Clinic Medical Center
10:35 AM
|
Applying Covariate-Adjusted, Response-Adaptive Randomization to Medical Device Studies
Thomas E. Gwise, FDA; Gene Anthony Pennello, FDA
10:55 AM
|
Comparing Adaptive and Traditional Crossover Designs for Dose-Finding Trials
James A. Bolognese, Cytel Inc.; Nitin R. Patel, Cytel Inc.; Byron Jones, Pfizer Inc.
11:15 AM
|
Adaptive Designs with Sensitive Subgroup Selection
Yan Daniel Zhao, Eli Lilly and Company; Alex Dmitrienko, Eli Lilly and Company
11:15 AM
|
I-SPY2: Identifying Biomarker Signatures for Therapeutic Agents in Neoadjuvant Breast Cancer
Donald Arthur Berry, MD Anderson Cancer Center; Kyle Wathen, MD Anderson Cancer Center; Nebiyou Bekele, MD Anderson Cancer Center; Laura Esserman, University of California, San Francisco
11:35 AM
|
An Adaptive Two-Step Procedure to Control Mean Number of False Discoveries
Dongmei Li, The University of Hawaii at Manoa
2:05 PM
|
Overall FDR Control in a Two-Stage Adaptive Design
Jingjing Chen, Temple University; Sanat K. Sarkar, Temple University
2:20 PM
|
Generalized Hypothesis Testing in Interim Treatment Selection with a Flexible Selection Margin
Yujun Wu, Sanofi-Aventis; Peng-Liang Zhao, sanofi-aventis
2:35 PM
|
Partially Adaptive Estimation of Truncated Regression Models: A Comparison with Several Semiparametric Estimators
Patrick Ansel Turley, Brigham Young University; James B McDonald, Brigham Young University
2:35 PM
|
Improving the Interim Analysis Process in Adaptive Design Trials
Xiaoyin Fan, Merck & Co., Inc.; Mary Varughese, Merck & Co., Inc.
2:50 PM
|
Confidence Intervals for the Selected Treatment Effect in Multistage Adaptive Designs
Ionut Bebu, Georgetown University Medical Center; Vladimir Dragalin, Pfizer Inc.; George Luta, Georgetown University
3:20 PM
|
|
Wednesday, 08/04/2010
|
Comparison of Estimation Methods for Logistic Regression Models with Multiple Random Effects Between Statistical Packages
Yoonsang Kim, Institute of Health Research and Policy; Young-Ku Choi, Institute of Health Research and Policy; Sherry Emery, Institute of Health Research and Policy
|
Statistical Issues in Adaptive Design
Wei Zhang, FDA/CVM
|
Forecasting Clinical Trial Enrollment: A Case Study
Zachary Skrivanek, Eli Lilly and Company
9:05 AM
|
Bayesian Adaptive Phase II/III Clinical Trial Design Using the Relationship Between Tumor Response and Survival
Donald Arthur Berry, MD Anderson Cancer Center; Haiying Pang, MD Anderson Cancer Center
9:20 AM
|
Adaptive Contact Strategies in Telephone and Face-to-Face Surveys
James Wagner, University of Michigan
10:05 AM
|
The Advantageous Adaptive Randomization in Clinical Trials
Bob Zhong, Johnson & Johnson
10:35 AM
|
A Finite Sample Study of a New Adaptive Nonparametric Method for Quantal Bioassay in Diverse Models
Lizhen Lin, The University of Arizona; Rabi Bhattacharya, The University of Arizona
10:35 AM
|
Adaptive Nonparametric Variable Selection for Survival Data
Lisha Chen, Yale University
10:35 AM
|
On Two-Stage Adaptive Design
Gang Li, Johnson & Johnson; Yining Wang, Johnson & Johnson; Weichung J. Shih, University of Medicine and Dentistry of New Jersey
10:35 AM
|
Key Considerations for Simulations to Optimize Dose-Finding Trials
Natalie Cheung Hall, Eli Lilly and Company
10:35 AM
|
Estimating the Number of One-Step Beneficial Mutations
Andrzej Jan Wojtowicz, University of Idaho; Holly A. Wichman, University of Idaho; Paul Joyce, University of Idaho
10:50 AM
|
An Adaptive Futility Monitoring Method with Time-Varying Conditional Power Boundary
Ying Zhang, The University of Iowa; William Clarke, The University of Iowa
10:55 AM
|
A Theory for Testing Hypotheses Under Covariate-Adaptive Randomization
Jun Shao, University of Wisconsin-Madison; Xinxin Yu, University of Wisconsin-Madison; Bob Zhong, Johnson & Johnson
10:55 AM
|
Adaptive Fitting of Linear Mixed Effects Models with Correlated Random Effects
Guangxiang George Zhang, State University of New York at Stony Brook; John J. Chen, State University of New York at Stony Brook
11:05 AM
|
Flexible Modification of Survival Trials
Cyrus R. Mehta, Cytel Inc.; Mikhail P. Salganik, Cytel Inc.
11:15 AM
|
Covariate-Adjusted Response-Adaptive Randomization Design with Survival Responses
Hongjian Zhu, University of Virginia; Feifang Hu, University of Virginia
11:15 AM
|
Statistical Inference Following an Adaptive Design for Case-Driven Efficacy Study
Xiaoming Li, Merck Research Laboratories; Ivan S.F. Chan, Merck Research Laboratories; Keaven M. Anderson, Merck Research Laboratories
11:20 AM
|
Variable Selection via Smoothing Spline Adaptive Response Transformation
Wenxuan Zhong, University of Illinois
11:55 AM
|
Hierarchical Gaussian Power Prior Models for Adaptive Incorporation of Historical Information in Clinical Trials
Bradley P. Carlin, University of Minnesota; Brian P. Hobbs, University of Minnesota; Daniel Sargent, Mayo Clinic; Sumithra Mandrekar, Mayo Clinic
2:05 PM
|
Statistical Testing in Clinical Trial with Covariate Adaptive Randomization
H.M. James Hung, FDA; Sue-Jane Wang, FDA
2:05 PM
|
Analysis of Long-Period Variable Stars with Nonparametric Tests for Trend Detection
Woncheol Jang, The University of Georgia; Cheolwoo Park, The University of Georgia; Jeongyoun Ahn, The University of Georgia; Martin Hendry, University of Glasgow
2:05 PM
|
Adaptive Dose Finding Using the 'Maximizing Procedure': Case Study and Missing Data Simulation
Kenneth Liu, Merck & Co., Inc.
2:25 PM
|
Properties of Re-Randomization Tests in Clinical Trials with Adaptive Randomization
Stephen Lake, Genzyme Corporation; Cyrus R. Mehta, Cytel Inc.; L. J. Wei, Harvard University
2:35 PM
|
Case Study: Benefits of an Adaptive Clinical Trial Design in Oncology
Darcy Hille, Merck & Co., Inc.; Christine K. Gause, Merck Research Laboratories; Jason B. Clark, Merck Research Laboratories; Sarah Hoagey, Merck & Co., Inc.; Keaven M. Anderson, Merck Research Laboratories
2:50 PM
|
Predictive Probability Approach for the Design and Analysis of Response and Toxicity Data in Cancer Clinical Trials
J. Jack Lee, MD Anderson Cancer Center; Guosheng Yin, The University of Hong Kong; Nan Chen, M D Anderson Cancer Center
2:55 PM
|
Robust Transmission Disequilibrium Test for Family Trio Design
Min Yuan, Fudan University, China; Yaning Yang, University of Science and Technology of China; Xin Tian, National Institutes of Health; Gang Zheng, National Institutes of Health
3:05 PM
|
Strategies for Setting Up the Logistics in Early Phase Adaptive Design Clinical Trials
Eva R. Miller, ICON Clinical Research
3:05 PM
|
Discovering Personalized Therapy for Cystic Fibrosis by Reinforcement Learning
Yiyun Tang, The University of North Carolina at Chapel Hill; Michael Kosorok, The University of North Carolina at Chapel Hill
3:05 PM
|
|
Thursday, 08/05/2010
|
Adaptive Designs for Dose-Ranging Studies
Vladimir Dragalin, Pfizer Inc.
8:35 AM
|
Bayesian Adaptive Designs in Practice
Scott Berry, Berry Consultants, LLC; Jason Connor, Berry Consultants, LLC
9:00 AM
|
Localized Realized Volatility Modeling
Ying Chen, National University of Singapore; Wolfgang Haerdle, Humboldt University in Berlin; Uta Pigorsch, Universitaet Mannheim
9:00 AM
|
Adaptive Sample Size Re-Estimation in Oncology Trials
Pralay Mukhopadhyay, Bristol-Myers Squibb
9:20 AM
|
Issues to Consider in Selecting a Response-Adaptive Design for Dose-Finding Experiments
Nancy Flournoy, University of Missouri
9:25 AM
|
Considerations for Design and Data Analysis of Adaptive Superiority/Noninferiority Cardiovascular Trials
Hui Quan, sanofi-aventis; Mingyu Li, Celgene Corporation; Peng-Liang Zhao, sanofi-aventis; Meehyung Cho, sanofi-aventis; Ji Zhang, Sanofi-Aventis; Yujun Wu, Sanofi-Aventis
10:35 AM
|
Design and Trial Operational Considerations for a Phase II Two-Stage Adaptive Trial
Weili He, Merck & Co., Inc.; Madhuja Mallick, Merck & Co., Inc.; Yevgen Tymofyeyev, Merck & Co., Inc.; James A. Bolognese, Cytel Inc.
10:55 AM
|
Experience with Using Simulation Models to Plan for Drug Supply in Adaptive Trials
Nitin R. Patel, Cytel Inc.; Suvajit Samanta, Merck Research Laboratories; Pralay Senchaudhuri, Cytel Inc.; Christine Stocklin, Merck & Co., Inc.
11:15 AM
|
Secondary Phenotype Data Analysis in Case-Control Genomewide Association Studies
Huilin Li, National Cancer Institute; Mitchell H. Gail, National Cancer Institute; Sonja Berndt, National Cancer Institute; Nilanjan Chatterjee, National Cancer Institute
11:50 AM
|
Adaptive Multiple Testing Procedures Controlling the Familywise Error Rate
Sanat K. Sarkar, Temple University
11:50 AM
|
|